EMD 521873 in Advanced Solid Tumors, MTD Finding

Non-Hodgkin Lymphoma Clinical Trial

Official title:

A Phase 1, Open-Label, Two-Group, Dose- Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of EMD 521873 Alone and in Combination With Fixed Low Doses of Cyclophosphamide in Patients With Metastatic or Locally Advanced Solid Tumors or B-Cell Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01032681
• Other study ID #: EMR62235_001
• Status: Completed
• Phase: Phase 1
• First received: December 11, 2009
• Last updated: July 30, 2014
• Start date: December 2006
• Est. completion date: January 2012

Study information

• Verified date: October 2012
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Paul-Ehrlich-InstitutSwitzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose cyclophosphamide (CPA) in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma.

Secondary objectives are to evaluate pharmacokinetic, immunogenicity, overall and best clinical response, changes in tumor marker levels, survival and biological/immune responses to EMD 521873. A total of 78 patients are planned. Patients will remain on the dose throughout the trial. It is intended to administer 3 cycles (21 d each, or until progression or a xxx line therapy becomes necessary.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: January 2012
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. Male or female, aged = 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles

3. Histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesenchymal cancers) or B-cell non-Hodgkin lymphoma for which no standard therapy exists or after failure of standard therapy

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months

5. Adequate hematological function defined by WBC count = 3 x 109/L with absolute neutrophil count (ANC) = 1.5 x 109/L and lymphocyte count = 0.5 x 109/L; platelet count =100 x 109/L; hemoglobin =9 g/dL ( If the laboratory values for hemoglobin are outside the required entry level at Screening, a patient may receive a transfusion of RBC. A stable hemoglobin level of =9 mg/dL for at least 7 days must be achieved prior to receiving the first dose of study medication.)

6. Adequate hepatic function defined by a total bilirubin level = 1.5 times the upper limit of normal (ULN) and aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) levels = 2.5 x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels = 5 x ULN

7. No history of acute or chronic kidney disease and adequate renal function defined by an estimated creatinine clearance above 50 mL/min determined by 24-hour urine sampling or by the Cockcroft-Gault formula

8. Effective contraception for both male and female subjects if the risk of conception exists

Exclusion Criteria:

1. Prior IL-2 therapy within the last 6 months

2. Requirement for concurrent anticancer treatment (chemotherapy, radiotherapy, immune therapy, cytokine therapy except erythropoietin) or for concurrent systemic therapy with steroids or other immunosuppressive agents. Short-term administration of steroids (i.e. for allergic reactions) is allowed.

3. Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of treatment in this study

4. Acquired immune defects such as human immunodeficiency virus (HIV)

5. Systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma)

6. Organ transplant recipients

7. History of or active inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)

8. Chronic viral infections (e.g. hepatitis B virus [HBV], hepatitis C virus [HCV])

9. Uncontrolled hypertension (systolic >180 mmHg, diastolic >100 mmHg)

10. Known hypersensitivity reactions to any of the compounds of the study medication

11. Confirmed or clinically suspected brain metastases

12. Pregnancy (absence to be confirmed by beta-human chorionic gonadotropin [ß-HCG] test) or lactation period

13. Clinically significant (i.e. active) cardiovascular disease: Cerebral vascular accident /stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrhythmia requiring medication.

14. Pulmonary disease which, in the opinion of the investigator, might impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g. interstitial lung disease, severe chronic obstructive pulmonary disease)

15. All conditions which are associated with significant necroses of non tumor-bearing tissues like e.g. esophageal or gastroduodenal ulcers (< 6 months prior to enrolment), organ infarctions (< 6 months prior to enrolment) or active ischemic bowel disease

16. Presence of medically significant third space fluid (pericardial effusion or ascites/ pleural infusion requiring repetitive paracentesis)

17. Known alcohol or drug abuse

18. Participation in another clinical trial within the past 30 days before start of study treatment

19. All other significant diseases which, in the opinion of the investigator, might impair the patient's tolerance of study treatment.

20. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Non-Hodgkin Lymphoma

Intervention

Biological:
• EMD 521873
Dose escalation steps: Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg) Disease control and decision of continuation in patient who benefit from the treatment: Every second cycle
• EMD 521873
Dose escalation steps: Group 2: CPA plus 0,6mg/kg - 0,9mg/kg Disease control and decision of continuation in patient who benefit from the treatment: Every second cycle
• EMD 521873
Dose escalation steps: Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg) Disease control and decision of continuation in patient who benefit from the treatment: Every second cycle

Locations

Country	Name	City	State
Germany	Universitäts-Klinikum Mainz III.Medizinische Klinik	Mainz
Germany	Medizinische Klinik Universitätsklinikum Mannheim Medizinische Fakultät Mannheim	Mannheim
Switzerland	Istituto Oncologico della Svizzera Italiana Ospedale Regionale Bellinzona e Valli (IOSI)	Bellinzona
Switzerland	University of Lausanne Hospitals (CHUV) and Hospitals of Riveria-Chablais	Lausanne
Switzerland	Kantonsspital St. Gallen	St.Gallen

Sponsors (1)

Lead Sponsor	Collaborator
Merck KGaA

Countries where clinical trial is conducted

Germany,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the safety and tolerability of EMD 521873		First administration of any dose of EMD521873 until last administration plus 30 days.	Yes
Primary	To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma		Incidence of DLTs occurring during the first cycle of administration of any dose of EMD 521873 given alone on 3 times per cycle (group 1) or with fixed low-dose CPA plus EMD 521873 (group 2) or of EMD 521873 given alone on once per cycle (group 3).	Yes
Secondary	Characterize the PK profile of EMD 521873 alone or in combination with fixed lowdose CPA		Cycle 1-3 of EMD 521873 treatment	No
Secondary	Evaluate the immunogenicity of EMD 521873 alone or in combination with CPA measured by the induction of o Specific antibodies against the genetically modified IL-2 o Fc-IL2-specific antibodies o Anti-idiotype antibodies		Every EMD 521873 treatment cycle	No
Secondary	Collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with EMD 521873 alone or in combination with CPA		Every second EMD 521873 treatment cycle	No
Secondary	Evaluate survival		Until 1 year after the last patient received his last dose of EMD 521873	No
Secondary	Evaluate biological responses to EMD 521873 alone or in combination with CPA as measured by o Absolute cell numbers and ratios of lymphocyte subsets in defined combinations o Change in serum level of sIL2R and neopterin		Cycle 1-3 of EMD 521873 treatment	No